Oruka Therapeutics, Inc. (ORKA)
NASDAQ · Manufacturing · Pharmaceutical preparations
ORKA price, last 12 months
Key stats
- Previous close
- $95.74
- Open
- $96.70
- Day range
- $96.11 – $101.94
- 52-week range
- $25.23 – $115.52
- Volume
- 927.1K
- Avg volume (20 days)
- 1M
- Market cap
- $7.1B
Performance
Technicals and fundamentals
About Oruka Therapeutics, Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $7.1B